News

Jefferies Raises SAIC Price Target, Maintains Hold on Stock

Jefferies Raises SAIC Price Target, Maintains Hold on Stock

Jefferies Updates Price Target for Science Applications

Jefferies has recently increased its price target for Science Applications (NASDAQ: SAIC) from $140 to $148. This decision follows in-depth discussions with the company’s Chief Financial Officer, Prabu Natarajan, and Senior Vice President of Investor Relations, Joe DeNardi.

The insights gained from these conversations revealed several encouraging developments at SAIC. The company has been actively involved in a variety of bids throughout the year, totaling an impressive $14.5 billion so far. What’s particularly noteworthy is their success in surpassing expectations related to target accelerations and win rates.

Future Growth Expectations and Strategic Developments

Looking forward, SAIC projects organic growth of 2-3% in the second half of the year. This anticipated growth is supported by a rebound in operations and maintenance spending, along with the ongoing ramp-up of the DTAMM project and a significant $200 million extension for the USAF CBC2.

Additionally, SAIC is set to experience margin expansion, thanks to profitable civilian projects and a robust bidding pipeline. Specifically, a projected improvement of 10 basis points could add around $0.12 to the estimated earnings per share for the fiscal year 2025, which is currently projected at $8.10. The company is also focusing on boosting its free cash flow per share by about 10% each year, with a target increase from $9 to $12.

Commitment to Shareholder Value

During their discussions, SAIC’s CFO and SVP conveyed a clear financial outlook, emphasizing a balanced strategy that prioritizes growth and operational efficiency. They are dedicated to enhancing shareholder value by carefully managing bids and overall company performance. Jefferies’ adjustment of their price target reflects recognition of these positive trends and the potential for continued financial improvement at SAIC.

Recent Contract Wins and Financial Performance

In exciting news, Science Applications International Corp. (SAIC) recently won a significant $229 million contract from the U.S. Department of Defense. This contract aims to upgrade the IT capabilities of NORAD and USNORTHCOM, with SAIC leading efforts to automate current IT systems, manage cloud migrations, and provide skilled professionals.

For its most recent fiscal quarter, SAIC reported a 2% increase in revenue, despite a slight drop of 2% in EBITDA. This performance surpassed market expectations, leading to a revised projection for fiscal year 2025, now forecasting a 3% revenue growth along with a 4% growth in EBITDA. Following these strong results, Jefferies raised their price target for SAIC from $135 to $140, reflecting their confidence in the company’s progress.

Anticipated Challenges and Objectives

While the outlook appears positive, SAIC's executives noted potential challenges, like contract protests and the impact of election cycles on their book-to-bill targets. They are ambitiously aiming for a book-to-bill ratio of 1.2x by the first half of fiscal year 2026 and are targeting 5% organic revenue growth by the end of the same fiscal year. These recent developments illustrate SAIC's careful transition towards targeted growth and refined bidding strategies.

InvestingPro Insights

With Jefferies’ recent update, a closer look at existing data may offer valuable insights. Currently, SAIC holds a market capitalization of around $6.75 billion and has a forward P/E ratio of 21.93, indicating strong investor confidence in future earnings growth. Despite a slight revenue decline over the past year, SAIC has recorded a notable three-month total return of 15.86%, demonstrating solid market performance.

Management insights suggest a proactive approach, as ongoing share buybacks reflect confidence in the company's intrinsic value. Furthermore, maintaining dividends consistently for the past 12 years, coupled with a strong shareholder yield, bolsters its appeal for income-oriented investors. These dynamics highlight SAIC’s potential for sustained profitability, as validated by analysts.

Frequently Asked Questions

What did Jefferies change regarding SAIC's stock?

Jefferies raised its price target for SAIC shares to $148 while keeping a Hold rating.

How much does SAIC expect to grow in the second half of the year?

SAIC anticipates organic growth of 2-3% in the latter half of the year.

What is the significant contract SAIC secured recently?

SAIC secured a $229 million contract from the U.S. Department of Defense to enhance IT capabilities.

What were SAIC's recent revenue changes?

SAIC reported a 2% increase in revenue for the second fiscal quarter.

What is SAIC's long-term goal regarding revenue growth?

SAIC aims for a 5% organic revenue growth by the end of the fiscal year 2026.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 136

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 80

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 53

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 208

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 206

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 68

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 153

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 17

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 277

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 287

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Elections: How EP3 Technology Transformed Voting

Updated Category News Views 114

EP3 Technology Powers Transformative Election Insights ForecastEx, a dynamic subsidiary of Interactive Brokers (IBKR), achieved a remarkable feat by processing over $560 million in election contracts during the 2024 U.S. general election. The groundbreaking technology enabling this achievement is Connamara Technologies' EP3 matching engine, an innovative platform designed...

Continue Reading
GI Partners and Legacy Investing Transform Chicago Landmark

Updated Category News Views 269

Transforming a Chicago Landmark into a Modern Data Center The historic 300,500 square foot building located at 400 S. LaSalle Street, once the home of the Chicago Board Options Exchange, is set to undergo an exciting transformation. Through an acquisition announced recently, GI Partners and Legacy Investing, LLC have acquired this prominent property with the intention of...

Continue Reading
Radiotherapy Market to Hit $10.68B in 2031, Growth Ahead

Updated Category News Views 30

Radiotherapy Market's Projected Growth: What's Fueling It? It's no secret: the radiotherapy market is on an upward trajectory, heading toward a substantial $10.68 billion valuation by 2031. But what’s pushing this rocket? For starters, we’re looking at a steady compound annual growth rate (CAGR) of 6.0% from 2026 to 2031. Not too shabby in today’s volatile economic...

Continue Reading
Join the Class Action Against Newmont Corporation by April 2025

Updated Category News Views 254

Take Action: Class Action Against Newmont Corporation Levi & Korsinsky, LLP is reaching out to investors linked to Newmont Corporation, urging them to act before the April 1, 2025 deadline for joining a class action lawsuit. This lawsuit addresses alleged securities fraud that negatively impacted many of Newmont's investors. Understanding the Class Action The class action...

Continue Reading
InflaRx Unveils Promising Preclinical Findings for INF904

Updated Category News Views 76

InflaRx Unveils New Developments for INF904 InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company recognized for its innovative anti-inflammatory therapies targeting the complement system, has recently shared promising preclinical results for its oral C5aR inhibitor, INF904. This announcement took place at the 2024 European Meeting on Complement in Human Diseases...

Continue Reading